Undifferentiated small round cell sarcoma (USRCS) represents a highly heterogeneous group of tumors. A variety of specific gene fusions of USRCS have been reported, including CIC–FOXO4, CIC–NUTM1, BCOR–MAML3, and ZC3H7B–BCOR. Here we report a case of sarcoma harboring a rare recurrent CRTC1–SS18 gene fusion, which was considered as USRCS previously. This sarcoma was composed of nests of small round cells encapsulated in a fibrous stroma. Foci of necrosis and hemorrhage were observed in the tumor. Immunohistochemistry for anaplastic lymphoma kinase showed diffuse positivity. RNA-seq results revealed a chromosomal translocation of CRTC1 gene exon 1 on chromosome 19 with SS18 gene exon 2 on chromosome 18. Thereafter, fluorescence in-situ hybridization confirmed the presence of SS18 gene and CRTC1 gene break-apart, which manifested as the splitting of red and green signals into 2 parts. A previous study showed that CRTC1–SS18 fusion sarcoma and EWSR1–CREB1 fusion angiomatoid fibrous histiocytoma were clustered close in the expression profile. However, whether CRTC1–SS18 fusion sarcomas represent a high malignancy has been a matter of debate. Our study is a worthy addition to the series of rare rearrangements associated with sarcomas and may be of therapeutic relevance.
MachadoINavarroSLlombart-BoschA. Ewing sarcoma and the new emerging Ewing-like sarcomas: (cic and bcor-rearranged-sarcomas). A systematic review. Histol Histopathol. 2016;31(11):1169-1181.
2.
RenziSAndersonNDLightNGuptaA. Ewing-like sarcoma: an emerging family of round cell sarcomas. J Cell Physiol. 2019;234(6):7999-8007.
3.
RiggiNKnoechelBGillespieSM, et al. Ews-fli1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014;26(5):668-681.
4.
ChenSDenizKSungYSZhangLDrySAntonescuCR. Ewing sarcoma with erg gene rearrangements: a molecular study focusing on the prevalence of fus-erg and common pitfalls in detecting Ewsr1-erg fusions by fish. Genes Chromosomes Cancer. 2016;55(4):340-349.
5.
SpechtKZhangLSungYS, et al. Novel bcor-maml3 and zc3h7b-bcor gene fusions in undifferentiated small blue round cell sarcomas. Am J Surg Pathol. 2016;40(4):433-442.
6.
SchaeferIMDal CinPLandryLMFletcherCDMHannaGJFrenchCA. Cic-nutm1 fusion: a case which expands the spectrum of nut-rearranged epithelioid malignancies. Genes Chromosomes Cancer. 2018;57(9):446-451.
7.
SugitaSAraiYTonookaA, et al. A novel cic-foxo4 gene fusion in undifferentiated small round cell sarcoma: a genetically distinct variant of Ewing-like sarcoma. Am J Surg Pathol. 2014;38(11):1571-1576.
8.
AlholleAKaranianMBriniAT, et al. Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent crtc1-ss18 gene fusion. J Pathol. 2018;245(2):186-196.
9.
YoshimotoTTanakaMHommeM, et al. Cic-dux4 induces small round cell sarcomas distinct from Ewing sarcoma. Cancer Res. 2017;77(11):2927-2937.
10.
EnzingerFM. Angiomatoid malignant fibrous histiocytoma: a distinct fibrohistiocytic tumor of children and young adults simulating a vascular neoplasm. Cancer. 1979;44(6):2147-2157.
11.
ThwayKFisherC. Angiomatoid fibrous histiocytoma: the current status of pathology and genetics. Arch Pathol Lab Med. 2015;139(5):674-682.
12.
CostaMJWeissSW. Angiomatoid malignant fibrous histiocytoma. A follow-up study of 108 cases with evaluation of possible histologic predictors of outcome. Am J Surg Pathol. 1990;14(12):1126-1132.
13.
CheahALZouYLaniganC, et al. Alk expression in angiomatoid fibrous histiocytoma: a potential diagnostic pitfall. Am J Surg Pathol. 2019;43(1):93-101.
14.
RossiSSzuhaiKIjszengaM, et al. Ewsr1-creb1 and ewsr1-atf1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res. 2007;13(24):7322-7328.
15.
RaddaouiEDonnerLRPanagopoulosI. Fusion of the fus and atf1 genes in a large, deep-seated angiomatoid fibrous histiocytoma. Diagn Mol Pathol. 2002;11(3):157-162.
16.
BrohlASSolomonDAChangW, et al. The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent stag2 mutation. PLoS Genet. 2014;10(7):e1004475.
17.
AntonescuCRNafaKSegalNHDal CinPLadanyiM. Ews-creb1: a recurrent variant fusion in clear cell sarcoma—association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006;12(18):5356-5362.
18.
AbramovitchRTavorEJacob-HirschJ, et al. A pivotal role of cyclic amp-responsive element binding protein in tumor progression. Cancer Res. 2004;64(4):1338-1346.
19.
HuPCLiKTianYH, et al. Creb1/lin28/mir-638/vasp interactive network drives the development of breast cancer. Int J Biol Sci. 2019;15(12):2733-2749.
20.
ConkrightMDCanettieriGScreatonR, et al. Torcs: transducers of regulated creb activity. Mol Cell. 2003;12(2):413-423.
21.
IourgenkoVZhangWMickaninC, et al. Identification of a family of camp response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Proc Natl Acad Sci USA. 2003;100(21):12147-12152.
22.
NakayamaTMiyabeSOkabeM, et al. Clinicopathological significance of the crtc3-maml2 fusion transcript in mucoepidermoid carcinoma. Mod Pathol. 2009;22(12):1575-1581.
23.
CellierLPerronEPissalouxD, et al. Cutaneous melanocytoma with crtc1-trim11 fusion: report of 5 cases resembling clear cell sarcoma. Am J Surg Pathol. 2018;42(3):382-391.
24.
EnlundFBehboudiAAndrenY, et al. Altered notch signaling resulting from expression of a wamtp1-maml2 gene fusion in mucoepidermoid carcinomas and benign Warthin’s tumors. Exp Cell Res. 2004;292(1):21-28.
25.
McBrideMJPuliceJLBeirdHC, et al. The ss18-ssx fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma. Cancer Cell. 2018;33(6):1128-1141e1127.
26.
MiddeljansEWanXJansenPWSharmaVStunnenbergHGLogieC. Ss18 together with animal-specific factors defines human baf-type swi/snf complexes. PLoS One. 2012;7(3):e33834.
27.
dos SantosNRTorensmaRde VriesTJ, et al. Heterogeneous expression of the ssx cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 2000;60(6):1654-1662.
28.
GureAOWeiIJOldLJChenYT. The ssx gene family: characterization of 9 complete genes. Int J Cancer. 2002;101(5):448-453.
29.
SmithHAMcNeelDG. The ssx family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol. 2010;2010:150591.
KadochCCrabtreeGR. Reversible disruption of mswi/snf (baf) complexes by the ss18-ssx oncogenic fusion in synovial sarcoma. Cell. 2013;153(1):71-85.
32.
BaranovEMcBrideMJBellizziAM, et al. A novel ss18-ssx fusion-specific antibody for the diagnosis of synovial sarcoma. Am J Surg Pathol. 2020;44(7):922-933.
33.
ZaborowskiMVargasACPulversJ, et al. When used together ss18-ssx fusion-specific and ssx c-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace fish or molecular testing in most cases. Histopathology. 2020;77(4):588-600.
34.
MarinoMTGrilliABaricordiC, et al. Prognostic significance of mir-34a in Ewing sarcoma is associated with cyclin d1 and ki-67 expression. Ann Oncol. 2014;25(10):2080-2086.
35.
ClasseMBurgessAEl ZeinS, et al. Evaluating the prognostic potential of the ki-67 proliferation index and tumour-infiltrating lymphocytes in olfactory neuroblastoma. Histopathology. 2019;75:853-864.
36.
WangHYLiZWSunW, et al. Automated quantification of ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors. Chin Med J (Engl) 2019;132(5):551-561.
37.
SollazzoMRBenassiMSMagagnoliG, et al. Increased c-myc oncogene expression in Ewing’s sarcoma: correlation with ki67 proliferation index. Tumori. 1999;85(3):167-173.
38.
McLeer-FlorinADuruisseauxMPinsolleJ, et al. Alk fusion variants detection by targeted rna-next generation sequencing and clinical responses to crizotinib in alk-positive non-small cell lung cancer. Lung Cancer. 2018;116:15-24.
39.
JangJSWangXVedellPT, et al. Custom gene capture and next-generation sequencing to resolve discordant alk status by fish and ihc in lung adenocarcinoma. J Thorac Oncol. 2016;11(11):1891-1900.
40.
ZhuVWLinYTKimDW, et al. An international real-world analysis of the efficacy and safety of lorlatinib through early or expanded access programs in patients with tyrosine kinase inhibitor-refractory alk-positive or ros1-positive nsclc. J Thorac Oncol. 2020;15(9):1484-1496.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
